Fc-optimized checkpoint antibodies for cancer immunotherapy

Rony Dahan; Alan J. Korman

doi:https://doi.org/10.1016/j.molmed.2024.10.008

Fc-optimized checkpoint antibodies for cancer immunotherapy

Rony Dahan, Alan J. Korman

Department of Systems Immunology

Weizmann Institute of Science

Research output: Contribution to journal › Article › peer-review

Abstract

The development of checkpoint antibodies for cancer therapy has been guided by the principle of blocking T cell inhibitory signals. Recognition of the role of the Fc domain in therapeutic activities, through the depletion of immunosuppressive populations and myeloid cell activation, prompts a shift toward the development of optimized Fc-engineered checkpoint antibodies.

Original language	English
Journal	Trends in Molecular Medicine
DOIs	https://doi.org/10.1016/j.molmed.2024.10.008
State	Published Online - 1 Nov 2024

Access to Document

https://doi.org/10.1016/j.molmed.2024.10.008

Cite this

@article{19f2c5764fcc4863a855c3c15bbc1bf5,

title = "Fc-optimized checkpoint antibodies for cancer immunotherapy",

abstract = "The development of checkpoint antibodies for cancer therapy has been guided by the principle of blocking T cell inhibitory signals. Recognition of the role of the Fc domain in therapeutic activities, through the depletion of immunosuppressive populations and myeloid cell activation, prompts a shift toward the development of optimized Fc-engineered checkpoint antibodies.",

author = "Rony Dahan and Korman, {Alan J.}",

year = "2024",

month = nov,

day = "1",

doi = "https://doi.org/10.1016/j.molmed.2024.10.008",

language = "الإنجليزيّة",

journal = "Trends in Molecular Medicine",

issn = "1471-4914",

publisher = "Elsevier Ltd.",

}

TY - JOUR

T1 - Fc-optimized checkpoint antibodies for cancer immunotherapy

AU - Dahan, Rony

AU - Korman, Alan J.

PY - 2024/11/1

Y1 - 2024/11/1

N2 - The development of checkpoint antibodies for cancer therapy has been guided by the principle of blocking T cell inhibitory signals. Recognition of the role of the Fc domain in therapeutic activities, through the depletion of immunosuppressive populations and myeloid cell activation, prompts a shift toward the development of optimized Fc-engineered checkpoint antibodies.

AB - The development of checkpoint antibodies for cancer therapy has been guided by the principle of blocking T cell inhibitory signals. Recognition of the role of the Fc domain in therapeutic activities, through the depletion of immunosuppressive populations and myeloid cell activation, prompts a shift toward the development of optimized Fc-engineered checkpoint antibodies.

U2 - https://doi.org/10.1016/j.molmed.2024.10.008

DO - https://doi.org/10.1016/j.molmed.2024.10.008

M3 - مقالة

SN - 1471-4914

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

ER -